CN Patent

CN117042771A — 使用serd给药方案的组合治疗癌症的方法

Assigned to Eli Lilly and Co · Expires 2023-11-10 · 3y expired

What this patent protects

本文中公开了向需要这样的治疗的患者施用式I的化合物或其药学上可接受的盐的给药方案。所述给药方案包括辅助疗法。

USPTO Abstract

本文中公开了向需要这样的治疗的患者施用式I的化合物或其药学上可接受的盐的给药方案。所述给药方案包括辅助疗法。

Drugs covered by this patent

Patent Metadata

Patent number
CN117042771A
Jurisdiction
CN
Classification
—
Expires
2023-11-10
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.